cerrar
Tagged with access

Mario Klesse – Country Director, Janssen Norway
Janssen Norway’s Mario Klesse shares his first impressions of the Norwegian pharma market, his strategic priorities for the affiliate, how Janssen…

Marcel Plattner – President, vips, Switzerland
Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing…

Importing Drugs from Canada: America’s Zombieland Sequel
Market access and pricing expert Barbara Jaszewski outlines the issues inherent in the USA importing drugs from Canada and why such proposals retain…

PhRMA CEO on ‘Tireless’ Industry COVID-19 Response &…
Stephen J. Ubl, president and CEO of PhRMA, outlines the unprecedented collaboration and speed with which the biopharmaceutical industry has responded…

Stephen Farr – President & CEO, Zogenix
Zogenix’s Dr Stephen Farr shares his remarkable career journey from academia to industry, the company’s transition from pain therapeutics into…

Henrik Asmussen – General Manager, Amgen Switzerland
In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges,…

Ramona Sequeira – President, Takeda Pharmaceuticals USA;…
Takeda USA’s Ramona Sequeira outlines her expanded role as president of global portfolio commercialization, the crucial importance of investing in…

Bradley Campbell – President & COO, Amicus…
Brad Campbell, president and COO of US rare disease specialist Amicus, talks domestic and global product launches, the company’s first steps into…

Tatsuya Kaihara – Corporate Officer, Head of North America…
Tatsuya Kaihara, head of US operations for Japanese eyecare specialist Santen, describes his excitement at bringing two new ophthalmic advancements to…

Katharina Gasser – Managing Director, Biogen Switzerland…
Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why…

Urs Vögeli – Managing Director, Janssen Switzerland
Urs Vögeli, managing director for Janssen Switzerland, outlines the importance of the Swiss operations to Janssen, his interesting career journey,…

Market Access in Switzerland: Reimbursement Delays for 76% of New…
Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here